AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.48
-0.19 (-3.35%)
Jul 24, 2026, 1:23 PM EDT - Market open
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $8.32M in the quarter ending March 31, 2026, with 96.34% growth. This brings the company's revenue in the last twelve months to $79.21M, up 242.66% year-over-year. In the year 2025, AbCellera Biologics had annual revenue of $75.13M with 160.56% growth.
Revenue (ttm)
$79.21M
Revenue Growth
+242.66%
P/S Ratio
21.05
Revenue / Employee
$140,940
Employees
562
Market Cap
1.67B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.13M | 46.30M | 160.56% |
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
| Dec 31, 2019 | 11.61M | 2.78M | 31.49% |
| Dec 31, 2018 | 8.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Sarepta Therapeutics | 2.18B |
| Immunocore Holdings | 412.81M |
| Maravai LifeSciences Holdings | 204.73M |
| Ascentage Pharma Group International | 82.08M |
| Zymeworks | 81.26M |
| Stoke Therapeutics | 32.08M |
| Generate Biomedicines | 30.30M |
ABCL News
- 14 days ago - 3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts - TipRanks
- 16 days ago - AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 - Business Wire
- 17 days ago - AbCellera upgraded to Buy from Hold at Benchmark - TheFly
- 18 days ago - AbCellera apponts Lynn Seely to board of directors - TheFly
- 18 days ago - AbCellera Appoints Dr. Lynn Seely to its Board of Directors - Business Wire
- 5 weeks ago - Jazz Pharma, AbCellera ink antibody deal worth up to $876 million - Reuters
- 5 weeks ago - Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies - Business Wire
- 7 weeks ago - AbCellera appoints Victor Sandor to board of directors - TheFly